Login Register Cart 0
Generic placeholder image

Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1573-4064
ISSN (Online): 1875-6638

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Design, Synthesis, and Docking Studies of Thioimidazolyl Diketoacid Derivatives Targeting HIV-1 Integrase

Author(s): Nafiseh Karimi, Rouhollah Vahabpour Roudsari, Zahra Hajimahdi and Afshin Zarghi*

Volume 18, Issue 5, 2022

Published on: 10 January, 2022

Page: [616 - 628] Pages: 13

DOI: 10.2174/1573406417666210929124944

Price: $65

Abstract

Background: Integrase enzyme is a validated drug target to discover novel structures as anti-HIV-1 agents.

Objective: This study aimed at developing a novel series of thioimidazolyl diketoacid derivatives characterizing various substituents at N-1 and 2-thio positions of the central ring as HIV-1integrase inhibitors.

Methods: In this study, eighteen novel thioimidazolyl DKA derivatives were synthesized in a fivestep parallel procedure and tested in vitro for the inhibition of both IN ST reaction and the singlecycle HIV-1 replication in HeLa cell culture.

Results: The obtained molecules were evaluated using the enzyme assay, displaying promising integrase inhibitory activity with IC50 values ranging from 0.9 to 7.7 mM. The synthesized compounds were also tested for antiviral activity and cytotoxicity using HeLa cells infected by the single-cycle replicable HIV-1 NL4-3.

Conclusion: The most potent compound was found to be 18i with EC50 = 19 μM, IC50 = 0.9 μM, and SI = 10.5. Docking studies indicated that the binding mode of the active molecule is well aligned with the known HIV-1integrase inhibitor.

Keywords: Design, synthesis, thioimidazolyl diketoacid, HIV-1, integrase, docking.

« Previous
Graphical Abstract

[1]
Barouch, D.H.; Deeks, S.G. Immunologic strategies for HIV-1 remission and eradication. Science, 2014, 345(6193), 169-174.
[http://dx.doi.org/10.1126/science.1255512] [PMID: 25013067]
[2]
Chun, T.W.; Fauci, A.S. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS, 2012, 26(10), 1261-1268.
[http://dx.doi.org/10.1097/QAD.0b013e328353f3f1] [PMID: 22472858]
[3]
Kinch, M.S.; Patridge, E. An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs. Drug Discov. Today, 2014, 19(10), 1510-1513.
[http://dx.doi.org/10.1016/j.drudis.2014.05.012] [PMID: 24880109]
[4]
Mehellou, Y.; De Clercq, E. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J. Med. Chem., 2010, 53(2), 521-538.
[http://dx.doi.org/10.1021/jm900492g] [PMID: 19785437]
[5]
Trivedi, J.; Mahajan, D.; Jaffe, R.J.; Acharya, A.; Mitra, D.; Byrareddy, S.N. Recent Advances in the Development of Integrase Inhibitors for HIV Treatment. Curr. HIV/AIDS Rep., 2020, 17(1), 63-75.
[http://dx.doi.org/10.1007/s11904-019-00480-3] [PMID: 31965427]
[6]
Métifiot, M.; Marchand, C.; Pommier, Y. HIV integrase inhibitors:]20-year landmark and challenges. Adv. Pharmacol., 2013, 67, 75-105.
[http://dx.doi.org/10.1016/B978-0-12-405880-4.00003-2] [PMID: 23885999]
[7]
Yuan, P.; Gupta, K.; Van Duyne, G.D. Tetrameric structure of a serine integrase catalytic domain. Structure, 2008, 16(8), 1275-1286.
[http://dx.doi.org/10.1016/j.str.2008.04.018] [PMID: 18682229]
[8]
Engelman, A.; Cherepanov, P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat. Rev. Microbiol., 2012, 10(4), 279-290.
[http://dx.doi.org/10.1038/nrmicro2747] [PMID: 22421880]
[9]
Li, X.; Krishnan, L.; Cherepanov, P.; Engelman, A. Structural biology of retroviral DNA integration. Virology, 2011, 411(2), 194-205.
[http://dx.doi.org/10.1016/j.virol.2010.12.008] [PMID: 21216426]
[10]
Pommier, Y.; Johnson, A.A.; Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov., 2005, 4(3), 236-248.
[http://dx.doi.org/10.1038/nrd1660] [PMID: 15729361]
[11]
Chen, J.C.; Krucinski, J.; Miercke, L.J.; Finer-Moore, J.S.; Tang, A.H.; Leavitt, A.D.; Stroud, R.M. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc. Natl. Acad. Sci. USA, 2000, 97(15), 8233-8238.
[http://dx.doi.org/10.1073/pnas.150220297] [PMID: 10890912]
[12]
Wang, L.D.; Liu, C.L.; Chen, W.Z.; Wang, C.X. Constructing HIV-1 integrase tetramer and exploring influences of metal ions on forming integrase-DNA complex. Biochem. Biophys. Res. Commun., 2005, 337(1), 313-319.
[http://dx.doi.org/10.1016/j.bbrc.2005.08.274] [PMID: 16188234]
[13]
Cherepanov, P.; Maertens, G.N.; Hare, S. Structural insights into the retroviral DNA integration apparatus. Curr. Opin. Struct. Biol., 2011, 21(2), 249-256.
[http://dx.doi.org/10.1016/j.sbi.2010.12.005] [PMID: 21277766]
[14]
Rogolino, D.; Carcelli, M.; Sechi, M.; Neamati, N. Viral enzymes containing magnesium: Metal binding as a successful strategy in drug design. Coord. Chem. Rev., 2012, 256, 3063-3086.
[http://dx.doi.org/10.1016/j.ccr.2012.07.006]
[15]
Hajimahdi, Z.; Zarghi, A. Progress in HIV-1 integrase inhibitors: A review of their chemical structure diversity. Iran. J. Pharm. Res., 2016, 15(4), 595-628.
[PMID: 28243261]
[16]
Choi, E.; Mallareddy, J.R.; Lu, D.; Kolluru, S. Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase. Future Sci. OA, 2018, 4(9), FSO338.
[http://dx.doi.org/10.4155/fsoa-2018-0060] [PMID: 30416746]
[17]
Cocohoba, J.; Dong, B.J. Raltegravir: the first HIV integrase inhibitor. Clin. Ther., 2008, 30(10), 1747-1765.
[http://dx.doi.org/10.1016/j.clinthera.2008.10.012] [PMID: 19014832]
[18]
Shimura, K.; Kodama, E.N. Elvitegravir: a new HIV integrase inhibitor. Antivir. Chem. Chemother., 2009, 20(2), 79-85.
[http://dx.doi.org/10.3851/IMP1397] [PMID: 19843978]
[19]
Johns, B.A.; Kawasuji, T.; Weatherhead, J.G.; Taishi, T.; Temelkoff, D.P.; Yoshida, H.; Akiyama, T.; Taoda, Y.; Murai, H.; Kiyama, R.; Fuji, M.; Tanimoto, N.; Jeffrey, J.; Foster, S.A.; Yoshinaga, T.; Seki, T.; Kobayashi, M.; Sato, A.; Johnson, M.N.; Garvey, E.P.; Fujiwara, T. Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the dis-covery of dolutegravir (S/GSK1349572) and (S/GSK1265744). J. Med. Chem., 2013, 56(14), 5901-5916.
[http://dx.doi.org/10.1021/jm400645w] [PMID: 23845180]
[20]
Kawasuji, T.; Johns, B.A.; Yoshida, H.; Weatherhead, J.G.; Akiyama, T.; Taishi, T.; Taoda, Y.; Mikamiyama-Iwata, M.; Murai, H.; Kiya-ma, R.; Fuji, M.; Tanimoto, N.; Yoshinaga, T.; Seki, T.; Kobayashi, M.; Sato, A.; Garvey, E.P.; Fujiwara, T. Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles. J. Med. Chem., 2013, 56(3), 1124-1135.
[http://dx.doi.org/10.1021/jm301550c] [PMID: 23316884]
[21]
Markham, A. Bictegravir: First Global Approval. Drugs, 2018, 78(5), 601-606.
[http://dx.doi.org/10.1007/s40265-018-0896-4] [PMID: 29564777]
[22]
Pendri, A.; Meanwell, N.A.; Peese, K.M.; Walker, M.A. New first and second generation inhibitors of human immunodeficiency virus-1 integrase. Expert Opin. Ther. Pat., 2011, 21(8), 1173-1189.
[http://dx.doi.org/10.1517/13543776.2011.586631] [PMID: 21599420]
[23]
Hazuda, D.J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J.A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M.D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science, 2000, 287(5453), 646-650.
[http://dx.doi.org/10.1126/science.287.5453.646] [PMID: 10649997]
[24]
Marchand, C.; Zhang, X.; Pais, G.C.G.; Cowansage, K.; Neamati, N.; Burke, T.R., Jr; Pommier, Y. Structural determinants for HIV-1 inte-grase inhibition by beta-diketo acids. J. Biol. Chem., 2002, 277(15), 12596-12603.
[http://dx.doi.org/10.1074/jbc.M110758200] [PMID: 11805103]
[25]
Beare, KD; Coster, MJ Rutledge, PJ Diketoacid Inhibitors of HIV-1 Integrase: From L-708,906 to Raltegravir and Beyond. Curr Med Chem, 2012, 19, 1177-1192. WOS:000300644000009.
[26]
Gill, M.S.A.; Hassan, S.S.; Ahemad, N. Evolution of HIV-1 reverse transcriptase and integrase dual inhibitors: Recent advances and de-velopments. Eur. J. Med. Chem., 2019, 179, 423-448.
[http://dx.doi.org/10.1016/j.ejmech.2019.06.058] [PMID: 31265935]
[27]
Esposito, F.; Tramontano, E. Past and future. Current drugs targeting HIV-1 integrase and reverse transcriptase-associated ribonuclease H activity: single and dual active site inhibitors. Antivir. Chem. Chemother., 2014, 23(4), 129-144.
[http://dx.doi.org/10.3851/IMP2690] [PMID: 24150519]
[28]
Distinto, S.; Maccioni, E.; Meleddu, R.; Corona, A.; Alcaro, S.; Tramontano, E. Molecular aspects of the RT/drug interactions. Perspective of dual inhibitors. Curr. Pharm. Des., 2013, 19(10), 1850-1859.
[http://dx.doi.org/10.2174/1381612811319100009] [PMID: 23092286]
[29]
Costi, R.; Métifiot, M.; Esposito, F.; Cuzzucoli Crucitti, G.; Pescatori, L.; Messore, A.; Scipione, L.; Tortorella, S.; Zinzula, L.; Novellino, E.; Pommier, Y.; Tramontano, E.; Marchand, C.; Di Santo, R. 6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach. J. Med. Chem., 2013, 56(21), 8588-8598.
[http://dx.doi.org/10.1021/jm401040b] [PMID: 24124919]
[30]
Corona, A.; di Leva, F.S.; Rigogliuso, G.; Pescatori, L.; Madia, V.N.; Subra, F.; Delelis, O.; Esposito, F.; Cadeddu, M.; Costi, R.; Cosconati, S.; Novellino, E.; di Santo, R.; Tramontano, E. New insights into the interaction between pyrrolyl diketoacids and HIV-1 inte-grase active site and comparison with RNase H. Antiviral Res., 2016, 134, 236-243.
[http://dx.doi.org/10.1016/j.antiviral.2016.09.008] [PMID: 27659398]
[31]
Cuzzucoli Crucitti, G.; Métifiot, M.; Pescatori, L.; Messore, A.; Madia, V.N.; Pupo, G.; Saccoliti, F.; Scipione, L.; Tortorella, S.; Esposito, F.; Corona, A.; Cadeddu, M.; Marchand, C.; Pommier, Y.; Tramontano, E.; Costi, R.; Di Santo, R. Structure-activity relationship of pyrrol-yl diketo acid derivatives as dual inhibitors of HIV-1 integrase and reverse transcriptase ribonuclease H domain. J. Med. Chem., 2015, 58(4), 1915-1928.
[http://dx.doi.org/10.1021/jm501799k] [PMID: 25629256]
[32]
Costi, R.; Di Santo, R.; Artico, M.; Roux, A.; Ragno, R.; Massa, S.; Tramontano, E.; La Colla, M.; Loddo, R.; Marongiu, M.E.; Pani, A.; La Colla, P. 6-aryl-2,4-dioxo-5-hexenoic acids, novel integrase inhibitors active against HIV-1 multiplication in cell-based assays. Bioorg. Med. Chem. Lett., 2004, 14(7), 1745-1749.
[http://dx.doi.org/10.1016/j.bmcl.2004.01.037] [PMID: 15026063]
[33]
Tramontano, E.; Esposito, F.; Badas, R.; Di Santo, R.; Costi, R.; La Colla, P. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonu-clease H activity in vitro. Antiviral Res., 2005, 65(2), 117-124.
[http://dx.doi.org/10.1016/j.antiviral.2004.11.002] [PMID: 15708638]
[34]
Hajimahdi, Z.; Zarghi, A.; Zabihollahi, R.; Aghasadeghi, M.R. Synthesis, biological evaluation, and molecular modeling studies of new 1,3,4-oxadiazole- and 1,3,4-thiadiazole-substituted 4-oxo-4H-pyrido[1,2-a]pyrimidines as anti-HIV-1 agents. Med. Chem. Res., 2013, 22, 2467-2475.
[http://dx.doi.org/10.1007/s00044-012-0241-5]
[35]
Hajimahdi, Z.; Zabihollahi, R.; Aghasadeghi, M.R.; Zarghi, A. Design, synthesis and docking studies of new 4-hydroxyquinoline-3-carbohydrazide derivatives as anti-HIV-1 agents. Drug Res. (Stuttg.), 2013, 63(4), 192-197.
[http://dx.doi.org/10.1055/s-0033-1334964] [PMID: 23487403]
[36]
Sala, M.; Spensiero, A.; Esposito, F.; Scala, M.C.; Vernieri, E.; Bertamino, A.; Manfra, M.; Carotenuto, A.; Grieco, P.; Novellino, E.; Cadeddu, M.; Tramontano, E.; Schols, D.; Campiglia, P.; Gomez-Monterrey, I.M. Development and Identification of a Novel Anti-HIV-1 Peptide Derived by Modification of the N-Terminal Domain of HIV-1 Integrase. Front. Microbiol., 2016, 7, 845.
[http://dx.doi.org/10.3389/fmicb.2016.00845] [PMID: 27375570]
[37]
Trott, O.; Olson, A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem., 2010, 31(2), 455-461.
[http://dx.doi.org/10.1002/jcc.21334] [PMID: 19499576]
[38]
Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem., 1998, 19, 1639-1662.
[http://dx.doi.org/10.1002/(SICI)1096-987X(19981115)19:14<1639:AID-JCC10>3.0.CO;2-B]
[39]
HyperChem(TM) Professional 8.0, Hypercube, Inc.: 1115 NW 4th Street, Gainesville, Florida 32601, USA. 1998.
[40]
Shafiee, A.; Zarghi, A.; Dehpour, A.R. Synthesis and anti-inflammatory activity of 1-methyl-2-(4-X-benzoyl)pyrrolo[2,3-d]imidazole-5-carboxylates. Pharm. Sci., 1997, 3, 461-463.
[http://dx.doi.org/10.1111/j.2042-7158.1997.tb00303.x]
[41]
Hadizadeh, F.; Tafti, F.I. Syntheses of substituted 2-(2-alkylthio-1-benzyl-5-imidazolyl)-1,3,4-oxadiazoles. J. Heterocycl. Chem., 2002, 39, 841-844.
[http://dx.doi.org/10.1002/jhet.5570390434]
[42]
Hare, S.; Gupta, S.S.; Valkov, E.; Engelman, A.; Cherepanov, P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature, 2010, 464(7286), 232-236.
[http://dx.doi.org/10.1038/nature08784] [PMID: 20118915]
[43]
Hare, S.; Vos, A.M.; Clayton, R.F.; Thuring, J.W.; Cummings, M.D.; Cherepanov, P. Molecular mechanisms of retroviral integrase inhibi-tion and the evolution of viral resistance. Proc. Natl. Acad. Sci. USA, 2010, 107(46), 20057-20062.
[http://dx.doi.org/10.1073/pnas.1010246107] [PMID: 21030679]
[44]
Costi, R.; Métifiot, M.; Chung, S.; Cuzzucoli Crucitti, G.; Maddali, K.; Pescatori, L.; Messore, A.; Madia, V.N.; Pupo, G.; Scipione, L.; Tortorella, S.; Di Leva, F.S.; Cosconati, S.; Marinelli, L.; Novellino, E.; Le Grice, S.F.; Corona, A.; Pommier, Y.; Marchand, C.; Di Santo, R. Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse tran-scriptase. J. Med. Chem., 2014, 57(8), 3223-3234.
[http://dx.doi.org/10.1021/jm5001503] [PMID: 24684270]
[45]
Pescatori, L.; Métifiot, M.; Chung, S.; Masoaka, T.; Cuzzucoli Crucitti, G.; Messore, A.; Pupo, G.; Madia, V.N.; Saccoliti, F.; Scipione, L.; Tortorella, S.; Di Leva, F.S.; Cosconati, S.; Marinelli, L.; Novellino, E.; Le Grice, S.F.; Pommier, Y.; Marchand, C.; Costi, R.; Di Santo, R. N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase. J. Med. Chem., 2015, 58(11), 4610-4623.
[http://dx.doi.org/10.1021/acs.jmedchem.5b00159] [PMID: 25961960]

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy